Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Ahn, ER; Garrett-Mayer, E; Halabi, S; Mangat, PK; Calfa, CJ; Alva, AS; Suhag, VS; Hamid, O; Dotan, E; Yang, ES-H; Alese, OB; Yost, KJ; Marr, AS; Palmer, MC; Thompson, FL; Rygiel, AL; Anderson, ST; Islam, S; Schilsky, RL

Published Date

  • May 20, 2020

Published In

Volume / Issue

  • 38 / 15

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X